PECAM1 and neoplasm: Bev-NR also showed a significant increase in vascular normalization, marked by CD31/ASMA, suggesting the possibility that when bevacizumab treatment alone does not produce long-term hypoxia, it cannot generate a response in terms of tumor volume change or survival.